Design Therapeutics, Inc. DSGN
10.36 USD +0.21 (+2.02%)
Nov 3, 2026, 3:28 PM EST
10.17 Day range 10.58
6.16 52-week range 17.25
- YTD
- +10.39%
- 1 year
- +58.09%
Analyst view
Price target (mean) 7.00 -32.4% downside
Now 10.36
- Target (low)
- 4.00
- Target (mean)
- 7.00
- Target (high)
- 12.00
Ratings (0m) 3 1 buy · 2 hold · 0 sell
- Strong buy1
- Buy0
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.26667 | -0.30 – -0.25 | -0.21 | -27.0% | 0 | 0.0% | 3 |
| Next quarter | -0.285 | -0.31 – -0.26 | -0.20 | -42.5% | 0 | 0.0% | 2 |
| Current year | -0.90 | -0.93 – -0.88 | -1.19 | +24.4% | 0 | 0.0% | 3 |
| Next year | -1.21 | -1.31 – -1.04 | -0.90 | -34.8% | 0 | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 6, 2024 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| May 7, 2024 | Piper Sandler | Upgrade | Neutral | Overweight |
| Mar 20, 2024 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| Mar 20, 2024 | Wedbush | Reiterated | Neutral | Neutral |
| Nov 14, 2023 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Aug 15, 2023 | Wedbush | Downgrade | Outperform | Neutral |
| Aug 15, 2023 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Aug 15, 2023 | RBC Capital | Downgrade | Outperform | Sector Perform |
| May 10, 2023 | RBC Capital | Maintained | — | Outperform |
| May 10, 2023 | Wedbush | Maintained | — | Outperform |
| May 4, 2023 | Goldman Sachs | Upgrade | Sell | Neutral |
| Mar 15, 2023 | RBC Capital | Reiterated | — | Outperform |
| Dec 9, 2022 | SVB Leerink | Maintained | — | Outperform |
| Dec 8, 2022 | RBC Capital | Maintained | — | Outperform |
| Aug 9, 2022 | Wedbush | Maintained | — | Outperform |
| Jun 10, 2022 | Wedbush | Initiated | — | Outperform |
| May 24, 2022 | Goldman Sachs | Maintained | — | Sell |
| May 10, 2022 | SVB Leerink | Maintained | — | Outperform |
| May 2, 2022 | RBC Capital | Initiated | — | Outperform |
| Jan 19, 2022 | Goldman Sachs | Initiated | — | Sell |
| Apr 20, 2021 | SVB Leerink | Initiated | — | Outperform |
| Apr 20, 2021 | Goldman Sachs | Initiated | — | Neutral |
| Apr 20, 2021 | Piper Sandler | Initiated | — | Overweight |